Melbourne Magnetic Resonance (MMR) helps researchers analyse the structure, properties and interactions of molecules for pharmaceutical development, material sciences, and other biological and chemical applications.
MMR offers a suite of nuclear magnetic resonance spectrometers. This technology is useful for analysing potential new drugs and proteins that cannot be crystallised. It can also be used to investigate interactions between molecules, including between proteins and specific ligands (including candidate drugs) or target membranes.
MMR is based in the Bio21 Institute.
- 400 MHz JEOL spectrometer and autosampler
- 400 MHz Bruker Avance IIIHD wide-bore spectrometer with DNP
- 500 MHz Agilent DD2 spectrometer
- 500 MHz Bruker NEO spectrometer equipped with a QR-1H/19F/13C/15N cryoprobe and SampleJet
- 600 MHz Bruker Avance III spectrometer with TCI cryoprobe and BACS-60 autosampler
- 600 MHz Varian VNMRS narrow-bore 4-channel HFXY spectrometer and a suite of MAS and static probes
- 700 MHz Bruker Avance IIIHD spectrometer with TCI cryoprobe and SampleJet autosampler
- 800 MHz Bruker Avance II spectrometer with TCI cryoprobe and BACS-60 autosampler.
The platform is open to academic and industry researchers on a self-operating or a fee-for-service basis.
The platform can be used in conjunction with:
- Melbourne Protein Characterisation
- Bio21 Systems & Computational Biology.
Image: Peter Casamento
Phone: +61 3 8344 9665
More information on this platform can be found on the Research Gateway, which is available to all University of Melbourne academic and honorary staff, graduate researchers and professional staff. Please note, to access the Research Gateway, you will need to login with your University of Melbourne username and password.